Last reviewed · How we verify

NCT00431756: BE

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus

Active, enrolled Last updated 16 December 2025
What this trial tests

trial in Barrett Esophagus in 600 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 May 2002
Primary endpoint
1 May 2023
1 June 2026

Quick facts

Lead sponsorJohns Hopkins University
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment600
Start date1 May 2002
Primary completion1 May 2023
Estimated completion1 June 2026
Sites1 location across United States

Conditions studied

Sponsor

Johns Hopkins University

Who can join

Adults 18 to 95, any sex, with Barrett Esophagus or Esophageal Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Barrett Esophagus

Currently open trials in the same condition.

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00431756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing